Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
World Neurosurg ; 184: e518-e523, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38316178

RESUMO

OBJECTIVE: Social support can be divided into emotional support, tool support, and information support in function or mode. Emotional support is an encouragement, expressed as love and care, respect and value, encouragement and compassion, and psychological resilience due to adaptation to adversity and stressors, which is conducive to personal positive psychological adjustment and good functional status. This study aims to explore the status of resilience and social support in elderly stroke patients and examine the correlation between the 2 factors. METHODS: Convenience sampling was used to survey 280 elderly stroke ischemic patients admitted to the Department of Neurology in our hospital from January to December 2020. General information, resilience, and social support were assessed through questionnaires. RESULTS: The participants had a moderate level of resilience, with an average score of 63.77 ± 9.99. The total social support score ranged with an average score of 33.72 ± 5.77, indicating a relatively low level of social support. After the Pearson correlation analysis, there was a positive correlation between resilience and social support, namely, r = 0.277, P < 0.05. CONCLUSIONS: Enhancing social support among elderly stroke patients is an effective way to improve their psychological resilience.


Assuntos
AVC Isquêmico , Resiliência Psicológica , Acidente Vascular Cerebral , Humanos , Idoso , Apoio Social , Adaptação Psicológica , Inquéritos e Questionários
2.
Microb Pathog ; 137: 103795, 2019 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-31610219

RESUMO

Paratyphoid fever caused by Salmonella Paratyphi A is a serious public health problem in many countries. In order to and develop a live attenuated candidate vaccine of Salmonella Paratyphi A, a Salmonella pathogenicity island 2 (SPI2, approximate 40 kb) deletion mutant of Salmonella Paratyphi A was constructed by lambda Red recombination, then the biological characteristics and protective ability of the Salmonella Paratyphi A SPI2 mutant were evaluated. Our results showed that the growth and biochemical properties of the SPI2 mutant were consistent with that of its parent strain, and the mutant was stable with the loss of SPI2. The mice lethal test showed that the virulence of the SPI2 mutant was significantly decreased, it can colonize and persistent more than 14 days in the liver and spleen of mice. Vaccination with the SPI2 mutant in mice revealed no significant effect on body weight and clinical symptoms compared to control animals, and specific humoral and cellular immune responses were also significantly induced. Immunization of mice offered efficient protection against Salmonella Paratyphi A strain challenge at 14 days post vaccination based on mortality and clinical symptoms relative to control group. Overall, these findings suggested that SPI2 plays an important role in pathogenicity of Salmonella Paratyphi A, and the SPI2 mutant showed its potential to develop a live attenuated vaccine candidate.


Assuntos
Ilhas Genômicas , Febre Paratifoide/prevenção & controle , Vacinas contra Salmonella/administração & dosagem , Salmonella paratyphi A/genética , Vacinas Tíficas-Paratíficas/administração & dosagem , Animais , Anticorpos Antibacterianos/imunologia , Feminino , Humanos , Imunização , Fígado/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Febre Paratifoide/imunologia , Febre Paratifoide/microbiologia , Vacinas contra Salmonella/genética , Vacinas contra Salmonella/imunologia , Salmonella paratyphi A/imunologia , Salmonella paratyphi A/patogenicidade , Deleção de Sequência , Baço/imunologia , Vacinas Tíficas-Paratíficas/genética , Vacinas Tíficas-Paratíficas/imunologia , Virulência
3.
CNS Neurosci Ther ; 24(10): 889-896, 2018 10.
Artigo em Inglês | MEDLINE | ID: mdl-29722134

RESUMO

BACKGROUND: Major depressive disorder (MDD) is a mental disease characterized by depressed mood, lifetime anxiety, and deficits of learning and memory. Inhibition of phosphodiesterase 9 (PDE9) has been reported to improve rodent cognitive and memory function. However, the role of PDE9 in MDD, in particular its manifestations of depression and anxiety, has not been investigated. METHODS: We examined the protective effects of WYQ-C36D (C36D), a novel PDE9 inhibitor, against corticosterone-induced cytotoxicity, pCREB/CREB and BDNF expression by cell viability, and immunoblot assays in HT-22 cells. The potential effects of C36D at doses of 0.1, 0.5, and 1 mg/kg on stress-induced depression- and anxiety-like behaviors and memory deficits were also examined in mice. RESULTS: C36D significantly protected HT-22 cells against corticosterone-induced cytotoxicity and rescued corticosterone-induced decreases in cGMP, CREB phosphorylation, and BDNF expression. All these effects were otherwise blocked by the PKG inhibitor Rp-8-Br-PET-cGMPS (Rp8). In addition, when tested in vivo in stressed mice, C36D produced antidepressant-like effects on behavior, as shown by decreased immobility time both in the forced swimming and tail suspension tests. C36D also showed anxiolytic-like and memory-enhancing effects in the elevated plus-maze and novel object recognition tests. CONCLUSION: Our results show that inhibition of PDE9 by C36D produces antidepressant- and anxiolytic-like behavioral effects and memory enhancement by activating cGMP/PKG signaling pathway. PDE9 inhibitors may have the potential as a novel class of drug to treat MDD.


Assuntos
Corticosterona/toxicidade , GMP Cíclico/metabolismo , Depressão/tratamento farmacológico , Síndromes Neurotóxicas/tratamento farmacológico , Inibidores de Fosfodiesterase/uso terapêutico , Transdução de Sinais/efeitos dos fármacos , Animais , Proteína de Ligação a CREB/metabolismo , Linhagem Celular Transformada , Transtornos Cognitivos/tratamento farmacológico , Transtornos Cognitivos/etiologia , Depressão/psicologia , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Elevação dos Membros Posteriores/psicologia , Locomoção/efeitos dos fármacos , Masculino , Aprendizagem em Labirinto/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos ICR , Síndromes Neurotóxicas/etiologia , Reconhecimento Psicológico/efeitos dos fármacos , Restrição Física/efeitos adversos , Natação/psicologia
4.
CNS Neurosci Ther ; 24(7): 652-660, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29704309

RESUMO

AIMS: Depression is currently the most common mood disorder. Regulation of intracellular cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP) signaling by phosphodiesterase (PDE) inhibition has been paid much attention for treatment of depression. This study aimed to investigate the neuroprotective effects of Hcyb1, a novel PDE2 inhibitor, in HT-22 cells and antidepressant-like effects in mouse models of depression. METHODS: Hcyb1 was synthesized and its selectivity upon PDE2 was tested. Moreover, HT-22 hippocampal cells were used to determine the effects of Hcyb1 on cell viability, cyclic nucleotide levels, and the downstream molecules related to cAMP/cGMP signaling by neurochemical, enzyme-linked immunosorbent, and immunoblot assays in vitro. The antidepressant-like effects of Hcyb1 were also determined in the forced swimming and tail suspension tests in mice. RESULTS: Hcyb1 had a highly selective inhibition of PDE2A (IC50  = 0.57 ± 0.03 µmol/L) and over 250-fold selectivity against other recombinant PDE family members. Hcyb1 at concentrations of 10-10 and 10-9  mol/L significantly increased cell viability after treatment for 24 hours. At concentrations of 10-9 ~10-7  mol/L, Hcyb1 also increased cGMP levels by 1.7~2.3 folds after 10-minute treatment. Furthermore, Hcyb1 at the concentrations of 10-9  mol/L increased both cGMP and cAMP levels 24 hours after treatment. The levels of phosphorylation of CREB and BDNF were also increased by Hcyb1 treatment in HT-22 cells for 24 hours. Finally, in the in vivo tests, Hcyb1 (0.5, 1, and 2 mg/kg, i.g.) decreased the immobility time in both forced swimming and tail suspension tests, without altering locomotor activity. CONCLUSION: These results suggest that the novel PDE2 inhibitor Hcyb1 produced neuroprotective and antidepressant-like effects most likely mediated by cAMP/cGMP-CREB-BDNF signaling.


Assuntos
Antidepressivos/uso terapêutico , Depressão/tratamento farmacológico , Guanina/análogos & derivados , Naftalenos/uso terapêutico , Neurônios/efeitos dos fármacos , Fármacos Neuroprotetores/uso terapêutico , Inibidores de Fosfodiesterase/uso terapêutico , Animais , Antidepressivos/química , Antidepressivos/farmacologia , Fator Neurotrófico Derivado do Encéfalo/genética , Fator Neurotrófico Derivado do Encéfalo/metabolismo , Proteína de Ligação a CREB/genética , Proteína de Ligação a CREB/metabolismo , Linhagem Celular Transformada , AMP Cíclico/metabolismo , GMP Cíclico/metabolismo , Modelos Animais de Doenças , Guanina/química , Guanina/farmacologia , Guanina/uso terapêutico , Elevação dos Membros Posteriores/métodos , Concentração Inibidora 50 , Locomoção/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos ICR , N-Metilaspartato/toxicidade , Naftalenos/química , Naftalenos/farmacologia , Fármacos Neuroprotetores/química , Fármacos Neuroprotetores/farmacologia , Inibidores de Fosfodiesterase/química , Inibidores de Fosfodiesterase/farmacologia , Natação
5.
J Ethnopharmacol ; 151(1): 591-600, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24269777

RESUMO

ETHNOPHARMACOLOGICAL RELEVANCE: Moutan Cortex (MC, family: Paeonia suffruticosa Andr.) is a well-known traditional herbal medicine that has been shown to hold a protective effect on inflammation in several diseases. However, its anti-inflammatory activity on diabetic nephropathy (DN) has been less reported. The present study was conducted to evaluate the potential attenuation activities of MC on inflammation in AGEs-induced rat mesangial cells dysfunction and high-glucose-fat diet and streptozotocin (STZ)-induced DN rats and explore the possible mechanism underlying its DN effect. MATERIALS AND METHODS: The inflammation in mesangial cells (HBZY-1) was induced by 200 µg/ml advanced glycation end products (AGEs). DN rats model was established by an administration high-glucose-fat diet and an intraperitoneal injection of STZ (30 mg/kg). Interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1) level in cell supernatant and rats serum were detected by appropriate kits. A co-culture system of mesangial cells and macrophages was performed to evaluate the migration of macrophages. Immunohistochemical assay was applied to examine transforming growth factor beta1 (TGF-ß1), IL-6, MCP-1 and intercellular adhesion molecule-1 (ICAM-1) expression in kidney tissues of rats. Furthermore, western blot analysis was carried out to examine TGF-ß1, IL-6, MCP-1, ICAM-1 and RAGE protein expressions in mesangial cells. RESULTS: Pretreatment with MC could significantly inhibit AGEs-induced migration of macrophages in the co-culture system of mesangial cell and macrophage. MC could decrease IL-6 and MCP-1 levels in serum of DN rats in a dose-dependent manner. Furthermore, MC also improved the blood glucose, serum creatinine and urine protein levels. Both immunocytochemistry analysis and western blot analysis showed that MC decreased significantly the over-expression of IL-6, MCP-1, TGF-ß1, ICAM-1 and RAGE in mesangial cells or kidney tissues. Additionally, the protein expression of proinflammatory cytokine could also be down-regulated by the pretreatment of RAGE-Ab (5 µg/ml). CONCLUSION: These findings indicated that the extract of MC had an amelioration activity on the inflammation in AGEs-induced mesangial cells dysfunction and high-glucose-fat diet and STZ-induced DN rats. The protective effect might be associated with the intervention of MC via target of RAGE. These findings suggested that MC might be a benefit agent for the prevention and treatment of DN.


Assuntos
Diabetes Mellitus Experimental/complicações , Gorduras na Dieta/efeitos adversos , Medicamentos de Ervas Chinesas/farmacologia , Glucose/efeitos adversos , Produtos Finais de Glicação Avançada/toxicidade , Células Mesangiais/efeitos dos fármacos , Animais , Anti-Inflamatórios/química , Anti-Inflamatórios/farmacologia , Linhagem Celular , Nefropatias Diabéticas/tratamento farmacológico , Relação Dose-Resposta a Droga , Medicamentos de Ervas Chinesas/química , Regulação da Expressão Gênica/efeitos dos fármacos , Glucose/administração & dosagem , Células Mesangiais/metabolismo , Paeonia/química , Distribuição Aleatória , Ratos
6.
Fa Yi Xue Za Zhi ; 24(4): 256-8, 2008 Aug.
Artigo em Chinês | MEDLINE | ID: mdl-18817033

RESUMO

OBJECTIVE: To examine the self-reported scale of brief psychopathological symptoms (SBPS) to detect malingering in forensic psychiatric cases. METHODS: Two hundred and six cases with different types of psychiatric problems were tested by SBPS. All cases were separately evaluated by two experts. RESULTS: About 34.5% cases (71/206) were classified as malingering by the cut-off 13 scores of SBPS. Compared with expert's evaluation, SBPS showed a false negative rate of 19.8% and a false positive rate of 1.7%, respectively, with a total accuracy rate of 90.8%. Cases involved in compensations including working injury and traffic accidence showed the highest rate of malingering (51%). CONCLUSION: SBPS is useful for detecting malingering psychopathological symptoms.


Assuntos
Psiquiatria Legal , Simulação de Doença/diagnóstico , Transtornos Mentais/psicologia , Testes Psicológicos , Adulto , Feminino , Humanos , Detecção de Mentiras , Masculino , Simulação de Doença/psicologia , Reprodutibilidade dos Testes , Volição , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...